Seaport Therapeutics director granted 12,258 stock options

Seaport Therapeutics director Sandra E. Peterson received a grant of stock options representing 12,258 shares of common stock.

Rhea-AI Filing Summary

Seaport Therapeutics director Sandra E. Peterson received a grant of stock options representing 12,258 shares of common stock. The options have an exercise price of $18.00 per share and expire on April 29, 2036. According to the footnote, all 12,258 underlying shares vest in full on April 30, 2027, subject to her continued service with the company.

Insights

Equity compensation analyst

Routine option grant to outside director; no open-market buying or selling.

Seaport Therapeutics awarded director Sandra E. Peterson 12,258 stock options with a strike price of $18.00 per share, expiring on April 29, 2036. This is recorded as a grant/award, not a market trade.

The footnote states these options vest in full on April 30, 2027, conditioned on continued service. With 12,258 options reported as held after the transaction and no sales, this looks like standard non-cash board compensation rather than a signal-driven insider purchase or sale.

Insider Trade Summary

Grant/Award: 12,258 shares

Grant/Award 1 txn

Insider PETERSON SANDRA E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	12,258	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 12,258 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 12,258 options Exercise price: $18.00 per share Expiration date: April 29, 2036 +2 more

5 metrics

Options granted 12,258 options Stock Option (Right to Buy) granted on April 30, 2026

Exercise price $18.00 per share Conversion or exercise price of options

Expiration date April 29, 2036 Option term end date

Vesting date April 30, 2027 Options vest in full subject to continued service

Holdings after transaction 12,258 options Total derivative securities directly owned after grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-04-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares underlying this option shall vest in full on April 30, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Seaport Therapeutics (SPTX) director Sandra E. Peterson report on this Form 4?

Sandra E. Peterson reported receiving a grant of stock options for 12,258 shares of Seaport Therapeutics common stock. The options were awarded at an exercise price of $18.00 per share and represent routine equity compensation rather than an open-market purchase or sale.

How many Seaport Therapeutics (SPTX) options did Sandra E. Peterson receive and at what price?

She received stock options covering 12,258 shares of Seaport Therapeutics common stock at an exercise price of $18.00 per share. This means she can buy those shares at $18.00 if and when the options vest and she chooses to exercise them.

When do Sandra E. Peterson’s Seaport Therapeutics (SPTX) options vest and expire?

The options vest in full on April 30, 2027, subject to her continued service on that date. They carry an expiration date of April 29, 2036, giving her several years after vesting to decide whether to exercise them.

Does this Seaport Therapeutics (SPTX) Form 4 show any stock being bought or sold on the market?

No, the Form 4 shows a grant of stock options, not an open-market trade. The transaction code is “A” for a grant or award acquisition, and transaction flags indicate it is neither a buy nor a sell in the open market.

How many Seaport Therapeutics (SPTX) derivative securities does Sandra E. Peterson hold after this transaction?

After this grant, she holds 12,258 derivative securities in the form of stock options, all directly owned. These options each relate to one share of common stock and together represent potential future ownership if exercised after vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PETERSON SANDRA E

(Last) (First) (Middle)

SEAPORT THERAPEUTICS, INC.

101 SEAPORT BLVD., FLOOR 12

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [ SPTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18	04/30/2026		A		12,258		(1)	04/29/2036	Common Stock	12,258	$0	12,258	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Lana Gladstein, Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)